{"id":1500,"date":"2024-08-30T21:56:24","date_gmt":"2024-08-30T19:56:24","guid":{"rendered":"https:\/\/studienportal-eierstockkrebs.de\/study-overview\/"},"modified":"2026-01-28T15:12:44","modified_gmt":"2026-01-28T14:12:44","slug":"study-overview","status":"publish","type":"page","link":"https:\/\/studienportal-eierstockkrebs.de\/en\/study-overview\/","title":{"rendered":"Study overview"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Study overview<\/strong>
Ovarian cancer<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Here you will find a list of all current studies in the field of ovarian cancer:<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Initial therapy<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n
\n
\n

AGO-OVAR 27- WoO<\/a><\/h3><\/header>
\n

AGO-OVAR 27 – WoO WoO: Window of Opportunity study on olaparib and durvalumab in histologically proven EOC Cohort A of the AGO-ovar 27 study has been fully recruited since January...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n<\/article>

\n
\n

NOGGO ov54 – SCOUT-1<\/a><\/h3><\/header>
\n

NOGGO ov54 – Scout 1 Observational study to collect data from the everyday routine of patients with ovarian cancer undergoing initial therapy SCOUT-1 is a non-interventional study, a so-called observational...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n<\/article>

\n
\n

N-PLUS<\/a><\/h3><\/header>
\n

NOGGO ov53\/ ENGOT-ov62 – N-Plus The world’s first study with the aim of reducing the number of chemotherapy cycles and thus the duration of chemotherapy in patients who have undergone...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n<\/article>

\n
\n

NIS CAROLIN<\/a><\/h3><\/header>
\n

NIS Niraparib – NOGGO-ov45 – CAROLIN For patients with platinum-sensitive ovarian cancer who have no contraindications to niraparib This non-interventional observational study aims to investigate the long-term treatment with niraparib...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n<\/article>

\n
\n

AGO-OVAR 28 \/ ENGOT-OV57<\/a><\/h3><\/header>
\n

AGO-OVAR 28 \/ ENGOT-ov57 A randomized open-label phase III study evaluating niraparib alone versus the combination of niraparib and bevacizumab in patients receiving chemotherapy for newly diagnosed advanced ovarian cancer...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n<\/article><\/div>\n

<\/div>\n <\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Recurrence therapy<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n
\n
\n

NIS Niraparib – NOGGO-ov45 – CAROLIN<\/a><\/h3><\/header>
\n

NIS Niraparib – NOGGO-ov45 – CAROLIN For patients with platinum-sensitive ovarian cancer who have no contraindications to niraparib This non-interventional observational study aims to investigate the long-term treatment with niraparib...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n<\/article>

\n
\n

ENGOT-ov83 \/ CATALINA-2<\/a><\/h3><\/header>
\n

ENGOT-ov83 \/ CATALINA-2 Therapeutic study to evaluate the efficacy and safety of the new compound TORL-1-23 in patients with advanced, platinum-resistant ovarian cancer CATALINA-2 is an international phase 2 trial...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n<\/article>

\n
\n

ENGOT-ov47-TR\/ NOGGO-TR2 – HELP-ER<\/a><\/h3><\/header>
\n

ENGOT-ov47-TR\/ NOGGO-TR2 – HELP-ER OBSERVATIONAL STUDY ON HE4 SERUM LEVELS IN THE BLOOD OF PATIENTS WITH FIRST RECURRENCE OF OVARIAN CANCER The HELP-ER study was designed to improve the treatment...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n<\/article>

\n
\n

AGO-OVAR 2.46 \/ ENGOT-ov81 \/ RAMP 301<\/a><\/h3><\/header>
\n

AGO-OVAR 2.46 \/ ENGOT-ov81 \/ RAMP 301 CLINICAL STUDY ON RECURRENT LOW-GRADE SEROUS OVARIAN CANCER The AGO-OVAR 2.46 \/ ENGOT-ov81 \/ RAMP 301 is a randomized, open-label phase III trial...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n<\/article>

\n
\n

NOGGO S15 – FraStROC<\/a><\/h3><\/header>
\n

NOGGO S15 – FraStROC Study for patients with recurrent or relapsed ovarian cancer. STUDY FOR PATIENTS WITH RECURRENT OR RELAPSED OVARIAN CANCER The FraStROC study is a non-interventional, prospective, multicenter...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n<\/article><\/div>\n

<\/div>\n <\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Surveys<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n
\n
\n

Expression XVIII (18)<\/a><\/h3><\/header>
\n

NOGGO S30\/ Expression XVIII (18) INTERNATIONAL SURVEY ON THE IMPACT OF CRISES ON PATIENTS WITH GYNECOLOGICAL TUMORS Anxiety is a central issue in cancer patients with gynecologic diseases and can...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n<\/article>

\n
\n

EXPRESSION IX (9)<\/a><\/h3><\/header>
\n

NOGGO S20 \/ ENGOTgyn4 – EXPRESSION IX (9) Long-term survival with gynecological cancer \/ Langzeit\u00fcberlebende mit gyn\u00e4kologischen Krebserrankungen Based on the experience with Expression VI – Carolin meets HANNA, a...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n<\/article>

\n
\n

NOGGO S19 – EXPRESSION VIII (8)<\/a><\/h3><\/header>
\n

NOGGO S19 – EXPRESSION VIII (8) For patients with a low-grade ovarian carcinoma (group A) or a borderline tumor of the ovary (group B – closed). Serous ovarian carcinoma is...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n<\/article>

\n
\n

EXPRESSION VI (6)<\/a><\/h3><\/header>
\n

NOGGO S13 \/ ENGOT-ov40 – EXPRESSION VI (6)CAROLIN MEETS HANNA For patients with ovarian, fallopian tube and peritoneal cancer who were diagnosed at least 5 years ago NEW: Instead of...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n<\/article>

\n
\n

EXPRESSION XX (20)<\/a><\/h3><\/header>
\n

NOGGO S33\/ Expression XX (20) SURVEY AMONG PATIENTS WITH GYNECOLOGICAL TUMORS ON HOW TO DELIVER BAD NEWS Breaking bad news is an essential part of everyday medical practice, especially in...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n<\/article><\/div>\n

<\/div>\n <\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tTo the map of Germany<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Study overviewOvarian cancer Here you will find a list of all current studies in the field of ovarian cancer: Initial therapy NOGGO ov54 – SCOUT-1 NOGGO ov54 – Scout 1 Beobachtungstudie zur Erfassung von Daten aus der Alltagsroutine von Patient:innen mit Ovarialkarzinom in der Ersttherapie\u00a0 SCOUT-1 ist eine nicht-interventionelle Studie, eine sogenannte Beobachtungstudie mit dem… […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-1500","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/pages\/1500","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/comments?post=1500"}],"version-history":[{"count":3,"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/pages\/1500\/revisions"}],"predecessor-version":[{"id":1538,"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/pages\/1500\/revisions\/1538"}],"wp:attachment":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/media?parent=1500"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}